gap27 peptide Latest Edition,Gap27

The gap 27 peptide, a synthetic molecule derived from connexin 43 (Cx43), has emerged as a significant tool in scientific research for its ability to selectively block gap junctions. This peptide, characterized by its conserved sequence homology to a portion of the second extracellular loop of Cx43, plays a crucial role in modulating intercellular communication. Its molecular weight is approximately 1304.5 Da, and its sequence is Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile. Understanding the mechanisms and applications of the gap 27 peptide is vital for advancing our knowledge in various biological and medical fields.

The primary function of the gap 27 peptide is as a gap junction inhibitor. Gap junctions are protein channels that connect the cytoplasm of adjacent cells, allowing for the direct exchange of ions and small molecules. By targeting the second extracellular loop of Cx43, Gap 27 effectively inhibits the formation and function of these channels, thereby disrupting intercellular communication. This property makes it invaluable for studying the specific roles of gap junctions in different physiological and pathological processes. Research has demonstrated that Gap 27 can inhibit GJIC (gap junction intercellular communication) by binding to this critical region of Cx43.

Beyond its role as a gap junction blocker, the gap 27 peptide has shown promise in various therapeutic contexts. For instance, studies have indicated that Gap 27 can be effective in promoting the healing of superficial epithelial wounds. Conversely, in deeper stromal wounds, it has the potential to influence inflammatory cell responses. This dual effect highlights the complex interplay between gap junctions and wound repair mechanisms. Furthermore, the Cx43 mimetic peptide Gap 27 has been investigated for its potential to ameliorate cardiac remodeling and arrhythmogenesis in heart failure models, suggesting a cardioprotective role.

The specificity of Gap 27 is a key aspect of its utility. While it primarily targets Cx43, variations like 40Gap 27 have been developed. The connexin mimetic peptide 40GAP27 corresponds to the GAP27 domain of the second extracellular loop of the dominant vascular connexin (Cx40). This distinction is important, as 40Gap 27 peptide does not regulate Cx43 in certain cell types, underscoring the importance of sequence specificity in mimetic peptides for targeted therapeutic interventions. Interestingly, Gap 27 does not inhibit dye transfer in cells expressing Cx40 but not Cx43, further confirming its selective action.

The scientific literature extensively documents the application of Gap 27 and related peptides in various research settings. Synthetic peptides like Gap26 and Gap27 have been utilized for over two decades to mimic short stretches of amino acids on the extracellular loops of connexins. Gap 27 has been employed as a blocking peptide for Cx43 gap junctions in specific cell cultures, such as follicular dendritic cells (FDC)-B cell cultures. Its ability to modulate gap junction communication makes it a versatile tool for investigating processes like antigen cross-presentation in dendritic cells.

Further research has explored the impact of connexin mimetic peptide Gap27 on cell migration. Studies have shown that Gap 27 increases the migration of human keratinocytes, a critical process for skin repair. This finding, along with the observation that Gap 27 and other connexin mimetic peptides targeted to the carboxyl terminal domain of Cx43 also improved cell migration rates in both 2D and 3D cultures, points to the significant role of Cx43 in cellular motility.

The therapeutic potential of connexin mimetic peptides extends to neurological conditions. The inhibition of connexin 43 by mimetic peptide Gap27 has been shown to mediate protective effects in a mouse model of Parkinson's disease induced by 6-hydroxydopamine. This suggests that modulating Cx43 function via peptides like Gap 27 could offer novel therapeutic strategies for neurodegenerative disorders.

In summary, the gap 27 peptide is a powerful research agent with diverse applications. As a selective gap junction blocker derived from connexin 43, it provides critical insights into cell-to-cell communication. Its demonstrated effects on wound healing, cardiac function, cell migration, and neurological protection underscore its significant therapeutic potential. The ongoing research into Gap 27 and other connexin mimetic peptides promises to further unravel the complexities of gap junction biology and pave the way for innovative treatments across a spectrum of diseases. The precise sequence of peptide4 (Gap27) and its targeted action on connexin proteins make it a valuable asset in the scientific community.